Skip to main content
National Screening Unit
National Screening Unit
  • Contact us
  • Publications
  • News
  • Home
  • About Us
    • Contact us
    • What is screening?
    • Screening programmes
    • Achieving our vision
    • Quality improvement
    • Advisory groups
    • Recommended links
    • Informed consent
    • About this site
  • Pregnancy & Newborn Screening
    • COVID-19: Information for pregnancy and newborn screening participants
    • Antenatal Screening for Down syndrome and Other Conditions
    • Newborn Metabolic Screening Programme - heel prick test
    • Universal Newborn Hearing Screening Programme
  • Bowel Screening
  • Breast & Cervical Screening
  • For Health Professionals
    • COVID-19: Information for screening providers
    • Antenatal Screening for Down syndrome and other Conditions
    • BreastScreen Aotearoa
    • National Bowel Screening Programme
    • National Cervical Screening Programme
    • Newborn Metabolic Screening Programme
    • Universal Newborn Hearing Screening Programme
    • Tools and resources
  1. Home
  2. Publications
  3. Cost-effectiveness of Newborn Screening for Severe Combined Immune Deficiency

Cost-effectiveness of Newborn Screening for Severe Combined Immune Deficiency

Image preview of Cost-effectiveness of Newborn Screening for Severe Combined Immune Deficiency resource
March, 2014
A report on testing for severe combined immune deficiency (SCID) in New Zealand as part of the Newborn Metabolic Screening Programme. It was prepared for the National Screening Unit by Health Partners Consulting Group Ltd.

View publication:

  • Cost-effectiveness of Newborn Screening for Severe Combined Immune Deficiency (pdf, 696 KB)
  • Home
  • Contact
  • Feedback
  • Glossary
  • Disclaimer
  • Privacy
  • Copyright
  • Accessibility
  • Publications
  • News
  • Ministry of Health
  • Time to Screen
govt.nz (opens in a new window). health.govt.nz website (opens in a new window).

© National Screening Unit 2023

Back to top